S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
NASDAQ:GTHX

G1 Therapeutics Stock Forecast, Price & News

$20.43
+0.12 (+0.59 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.86
Now: $20.43
$21.40
50-Day Range
$20.31
MA: $24.91
$32.59
52-Week Range
$8.80
Now: $20.43
$37.07
Volume1.89 million shs
Average Volume1.78 million shs
Market Capitalization$857.22 million
P/E RatioN/A
Dividend YieldN/A
Beta2.44
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
G1 Therapeutics logo

Headlines

G1 Therapeutics - Brighter Days Ahead
March 4, 2021 |  seekingalpha.com
Recap: G1 Therapeutics Q4 Earnings
February 25, 2021 |  finance.yahoo.com
Is GTHX A Good Stock To Buy Now?
December 14, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GTHX
CUSIPN/A
Phone919-213-9835
Employees104
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.80 per share

Profitability

Net Income$-122,450,000.00

Miscellaneous

Market Cap$857.22 million
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.51 out of 5 stars

Medical Sector

464th out of 1,968 stocks

Pharmaceutical Preparations Industry

227th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$20.43
+0.12 (+0.59 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GTHX News and Ratings via Email

Sign-up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

Is G1 Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" G1 Therapeutics stock.
View analyst ratings for G1 Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than G1 Therapeutics?

Wall Street analysts have given G1 Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but G1 Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for G1 Therapeutics
.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings data on Wednesday, February, 24th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.21. The firm had revenue of $16.55 million for the quarter, compared to analyst estimates of $14 million.
View G1 Therapeutics' earnings history
.

How has G1 Therapeutics' stock been impacted by Coronavirus (COVID-19)?

G1 Therapeutics' stock was trading at $14.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GTHX shares have increased by 41.0% and is now trading at $20.43.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for GTHX?

7 Wall Street analysts have issued 12 month target prices for G1 Therapeutics' stock. Their forecasts range from $21.00 to $82.00. On average, they expect G1 Therapeutics' share price to reach $49.17 in the next year. This suggests a possible upside of 140.7% from the stock's current price.
View analysts' price targets for G1 Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the following people:
  • Ms. Jennifer K. Moses, Chief Financial Officer (Age 46, Pay $441.6k)
  • Dr. Mark A. Velleca, Sr. Advisor & Director (Age 57, Pay $878.21k)
  • Dr. Rajesh K. Malik, Chief Medical Officer and Sr. VP of R&D (Age 62, Pay $560.17k)
  • Mr. Mark Avagliano, Chief Bus. Officer (Age 45, Pay $559.74k)
  • Mr. John E. Bailey Jr., CEO, Pres & Director (Age 56)
  • Mr. Terry L. Murdock, Chief Operating Officer (Age 61)
  • Mr. Alexander D. Smith M.S., VP of Technical Operations
  • Dr. Jay C. Strum, Chief Scientific Officer (Age 57)
  • Mr. Jeff Macdonald, Sr. Director of Investor Relations & Corp. Communications
  • Mr. Blake Jensen, VP of Quality & Compliance

Who are some of G1 Therapeutics' key competitors?

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.61%), JPMorgan Chase & Co. (4.39%), Price T Rowe Associates Inc. MD (4.08%), Nuveen Asset Management LLC (1.84%), Dimensional Fund Advisors LP (1.56%) and Hillhouse Capital Advisors LTD. (1.25%). Company insiders that own G1 Therapeutics stock include Glenn P Muir, James S Hanson, Mark A Velleca, Rajesh Malik and Seth Rudnick.
View institutional ownership trends for G1 Therapeutics
.

Which institutional investors are selling G1 Therapeutics stock?

GTHX stock was sold by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors LTD., Federated Hermes Inc., Squarepoint Ops LLC, Trexquant Investment LP, SG Americas Securities LLC, CHI Advisors LLC, Los Angeles Capital Management LLC, and Alliancebernstein L.P.. Company insiders that have sold G1 Therapeutics company stock in the last year include Mark A Velleca, Rajesh Malik, and Seth Rudnick.
View insider buying and selling activity for G1 Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying G1 Therapeutics stock?

GTHX stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, BlackRock Inc., Voloridge Investment Management LLC, Morgan Stanley, Barclays PLC, Price T Rowe Associates Inc. MD, Rhenman & Partners Asset Management AB, and Virginia Retirement Systems ET AL. Company insiders that have bought G1 Therapeutics stock in the last two years include Glenn P Muir, and James S Hanson.
View insider buying and selling activity for G1 Therapeutics
or or view top insider-buying stocks.

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $20.43.

How much money does G1 Therapeutics make?

G1 Therapeutics has a market capitalization of $857.22 million. The company earns $-122,450,000.00 in net income (profit) each year or ($3.27) on an earnings per share basis.

How many employees does G1 Therapeutics have?

G1 Therapeutics employs 104 workers across the globe.

What is G1 Therapeutics' official website?

The official website for G1 Therapeutics is www.g1therapeutics.com.

Where are G1 Therapeutics' headquarters?

G1 Therapeutics is headquartered at 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.